PTLA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTLA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Portola Pharmaceuticals's share price is $18.03. Portola Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2020 was $0.92. Hence, Portola Pharmaceuticals's PB Ratio of today is 19.64.
The historical rank and industry rank for Portola Pharmaceuticals's PB Ratio or its related term are showing as below:
The historical data trend for Portola Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Portola Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 6.78 | 6.66 | 9.16 | 14.71 | 14.33 |
Portola Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | |
PB Ratio | Get a 7-Day Free Trial | 48.74 | 3,014.44 | 9.80 | 14.33 | 7.77 |
For the Biotechnology subindustry, Portola Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Portola Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Portola Pharmaceuticals's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Mar. 2020) |
= | 18.03 | / | 0.918 | |
= | 19.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Portola Pharmaceuticals (NAS:PTLA) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Portola Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Dennis M Fenton | director | |
John B Moriarty | officer: EVP, General Counsel | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Hollings Renton | director | |
David C Stump | director | |
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Jeffrey W Bird | director | 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005 |
Henry Ward Wolff | director | 6701 KAISER DRIVE, FREMONT CA 94555 |
J. Scott Garland | director, officer: President and CEO | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Mardi Dier | officer: EVP and CFO | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Rajiv Patni | officer: EVP, CMO | C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
John T Curnutte | officer: EVP R&D | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Charles J Homcy | other: Former Director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
William Lis | director, officer: Chief Executive Officer | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired Marketwired • 03-12-2020
By PRNewswire PRNewswire • 05-05-2020
By PRNewswire PRNewswire • 05-14-2020
By PRNewswire PRNewswire • 03-16-2020
By PRNewswire PRNewswire • 03-14-2020
By PRNewswire PRNewswire • 03-16-2020
By Marketwired Marketwired • 03-09-2020
By Marketwired Marketwired • 03-10-2020
By BusinessWire BusinessWire • 03-16-2020
By PRNewswire PRNewswire • 03-05-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.